Literature DB >> 35412112

Imaging of neuroendocrine neoplasms of the male GU tract.

Kedar G Sharbidre1, Ajaykumar C Morani2, Mohd Zahid3, Priya Bhosale2, Chandana Lall4, Isaac R Francis5, Sadhna Verma6.   

Abstract

Male genitourinary neuroendocrine neoplasms (GU-NENs) are rare, without any definite imaging characteristics. The WHO classified neuroendocrine neoplasms in the 2016 classification of the tumors of the urinary tract and genital organs along with other GU tumors; however, no pathologic grading system is available as published for gastroenteropancreatic neuroendocrine neoplasms. Often a multimodality approach using cross-sectional imaging techniques, such as molecular imaging and histopathology are implemented to arrive at the diagnosis. This article provides a review of the pathology and imaging features of the male GU-NENs.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Genitourinary; Male; Neuroendocrine; Paraganglioma; Small cell neuroendocrine

Year:  2022        PMID: 35412112     DOI: 10.1007/s00261-022-03510-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  50 in total

1.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Authors:  Charles C Guo; Jane Y Dancer; Yan Wang; Ana Aparicio; Nora M Navone; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2010-10-30       Impact factor: 3.466

Review 2.  Molecular Imaging and Therapy for Neuroendocrine Tumors.

Authors:  Hemant Desai; Salvador Borges-Neto; Terence Z Wong
Journal:  Curr Treat Options Oncol       Date:  2019-08-29

3.  Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites.

Authors:  O Kaufmann; M Dietel
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

Review 4.  Neuroendocrine tumors of genitourinary tract: Recent advances.

Authors:  Ahmed N Shehabeldin; Jae Y Ro
Journal:  Ann Diagn Pathol       Date:  2019-06-21       Impact factor: 2.090

Review 5.  Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.

Authors:  Kai Duan; Ozgur Mete
Journal:  Cancer Cytopathol       Date:  2016-08-16       Impact factor: 5.284

Review 6.  Primary renal carcinoid: treatment and prognosis.

Authors:  Taner Korkmaz; Selcuk Seber; Dilek Yavuzer; Mahmut Gumus; N Serdar Turhal
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-09       Impact factor: 6.312

7.  Renal carcinoid tumor: a clinicopathologic study of 21 cases.

Authors:  Donna E Hansel; Jonathan I Epstein; Ema Berbescu; Samson W Fine; Robert H Young; John C Cheville
Journal:  Am J Surg Pathol       Date:  2007-10       Impact factor: 6.394

Review 8.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

Review 9.  Carcinoid tumor associated with adjacent dysplastic columnar epithelium in the renal pelvis: A case report and literature review.

Authors:  Sung Sun Kim; Chan Choi; Taek Won Kang; Yoo Duk Choi
Journal:  Pathol Int       Date:  2015-12-08       Impact factor: 2.534

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.